Let's remember that it typically takes up to two years for the full
effect of a lower dollar to be felt.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the
effect of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S.
dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Total CPI inflation remains near the bottom
of the Bank's target range as the disinflationary
effects of economic slack and
low consumer energy prices are only partially offset by the inflationary impact
of the
lower Canadian
dollar on the prices
of imported goods.
However, this was partly because
Dollar Bank provided no zero - point mortgages, meaning that its advertised rates included the
effect of purchasing mortgage points in order to
lower the final interest rate.
The negative
effects of lower oil prices hit the economy right away, and the various positives - more exports because
of a stronger U.S. economy and a
lower dollar, and more consumption spending as households spend less on fuel - will arrive only gradually, and are
of uncertain size.
Core inflation has been temporarily boosted by sector - specific factors and the pass - through
effects of the
lower Canadian
dollar, which are offsetting disinflationary pressures from slack in the economy and competition in the retail sector.
Some economists say the
effects of lowering the federal government's credit rating to AA from AAA can be measured in the billions
of dollars in increased borrowing costs for the government, and in the billions more that consumers, corporations, states and municipalities will have to pay for their credit.
The materials sector is 5 per cent
lower than at end October and has shown considerable volatility during the period because
of the conflicting
effects of strong increases in metals prices and concerns about the appreciation
of the Australian
dollar.
The economic benefits
of the hydropower also extend to the other enterprises in the area that the customers do business with, so there is an extensive multiplier
effect with billions
of dollars in gross regional production directly or indirectly linked to the
low - cost power.»
That means just ten cents
of every
dollar increase in appropriations would find their way into
lower tuition, an
effect similar in magnitude to what Rizzo and Ehrenberg found for an earlier time period.
These estimated earnings
effects, for both middle class and
low - income kids, are that for each
dollar invested in pre-K, the present value
of future earnings for those kids increases by about $ 5.
I've just realized that the Turnaround Model the state is so anxious to
effect on its «
lowest performing schools» and
of which Andrea Comer and Michael Sharpe are experts should actually be called the Turn Over Model — as in, Turn Over your public taxpayer
dollars to a private «non-profit» charter company, such as FUSE or Achievement First.
However, this was partly because
Dollar Bank provided no zero - point mortgages, meaning that its advertised rates included the
effect of purchasing mortgage points in order to
lower the final interest rate.
More than three - quarters
of the people who paid an overdraft penalty express concern about specific overdraft policies, including the high cost
of a penalty and the practices
of charging «extended» overdraft fees — additional charges for failing to repay a negative balance on time — and
of reordering withdrawals from highest to
lowest dollar amount, which have the
effect of increasing overdraft fees.
In June 2016, APS filed for a $ 3.6 billion rate increase (Docket E-01345A-16-0036) to go into
effect July 2017, including higher fixed charges, new demand charges for solar customers,
lowering the rate paid for distributed solar from the retail rate (12 - 13 cents / kWh) to wholesale rate (3 cents / kWh), and spending billions
of dollars to introduce fossil fuel plants, including one
of the Western U.S.'s oldest and dirtiest coal plants, into rate base.
That approach could be done for the
low billions
of dollars (far cheaper than either curtailing oil use or allowing a global warming catastrophe), and almost provably would work if we were sure
of the global warming
effect.